2026 ASCO Breast Cancer Highlights: HER2CLIMB-05 - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

2026 ASCO Breast Cancer Highlights: HER2CLIMB-05

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the HER2Climb-05 trial and how it impacts treatment for HER2+ metastatic breast cancer

  • October 15, 2026

Share

  • 1

    Harold Burstein, MD, PhD, and Adrienne Waks, MD, discuss the HER2CLIMB-05 trial.

  • 2

    The discussion focuses on treatment for HER2-positive metastatic breast cancer.

  • 3

    The title identifies HER2CLIMB-05 as a 2026 ASCO breast cancer highlight.

  • 4

    The provided context does not report the trial’s design or results.

  • 5

    The provided context does not specify how the trial affects treatment.

Original Source(s)

2026 ASCO Breast Cancer Highlights: HER2CLIMB-05

  • October 15, 2026

Related Content

Associations between CT characteristics of lung cancer lesions and histologic subtypes in lung cancer screening

Building a Pre-Disease Data Map

Mayo Clinic and Thermo Fisher launch a large-scale multi-omics resource designed to reveal disease before symptoms appear

  • October 7, 2026

  • 2 min
A Glimpse into the Future of Analytical Instrument Design?

Michael John Fanous’s portable scanner uses AI to reconstruct images blurred by continuous high-speed acquisition